Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.94% | 84.39 | 0.9% | $1036.86m | |
| KITE | Kite Pharma, Inc. | 0.18% | 179.63 | 16.1% | $788.56m | |
| CELG | Celgene Corporation | -0.54% | 144.16 | 1.1% | $523.32m | |
| AMGN | Amgen Inc. | -0.11% | 186.09 | 1.1% | $498.83m | |
| BIIB | Biogen Inc. | -0.39% | 316.27 | 1.2% | $434.32m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.44% | 436.24 | 2.7% | $368.68m | |
| ALNY | Alnylam Pharmaceuticals, Inc | -4.08% | 112.26 | 10.7% | $259.26m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -2.82% | 139.91 | 1.9% | $231.74m | |
| JUNO | Juno Therapeutics, Inc. | -1.51% | 41.69 | 14.6% | $228.03m | |
| INCY | Incyte Corporation | -0.57% | 109.07 | 2.6% | $223.78m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.02% | 149.14 | 1.9% | $216.38m | |
| ILMN | Illumina, Inc. | -1.07% | 199.22 | 3.5% | $163.28m | |
| BLUE | Bluebird Bio, Inc. | -2.20% | 127.63 | 19.3% | $146.09m | |
| BMRN | BioMarin Pharmaceutical Inc. | -1.42% | 93.05 | 4.4% | $140.45m | |
| CLVS | Clovis Oncology, Inc. | -3.83% | 73.05 | 18.0% | $132.30m |
Company Profile
Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.